181 related articles for article (PubMed ID: 15617598)
1. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.
Eller JL; Longo SL; Kyle MM; Bassano D; Hicklin DJ; Canute GW
Neurosurgery; 2005; 56(1):155-62; discussion 162. PubMed ID: 15617598
[TBL] [Abstract][Full Text] [Related]
2. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
3. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
4. Long term responses with cetuximab therapy in glioblastoma multiforme.
Belda-Iniesta C; Carpeño Jde C; Saenz EC; Gutiérrez M; Perona R; Barón MG
Cancer Biol Ther; 2006 Aug; 5(8):912-4. PubMed ID: 16929166
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
6. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
[TBL] [Abstract][Full Text] [Related]
8. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Combs SE; Schulz-Ertner D; Roth W; Herold-Mende C; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):873-82. PubMed ID: 17544000
[TBL] [Abstract][Full Text] [Related]
9. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E
Br J Cancer; 2009 Mar; 100(6):950-8. PubMed ID: 19293809
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
13. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
14. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
[TBL] [Abstract][Full Text] [Related]
15. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
[TBL] [Abstract][Full Text] [Related]
16. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma.
Hicks MJ; Chiuchiolo MJ; Ballon D; Dyke JP; Aronowitz E; Funato K; Tabar V; Havlicek D; Fan F; Sondhi D; Kaminsky SM; Crystal RG
PLoS One; 2016; 11(10):e0162978. PubMed ID: 27711187
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.
Yang SH; Hong YK; Jeun SS; Kim IS; Hong JT; Sung JH; Son BC; Lee SW; Kim MC; Lee KS
J Neurooncol; 2009 Oct; 95(1):23-28. PubMed ID: 19381443
[TBL] [Abstract][Full Text] [Related]
18. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
[TBL] [Abstract][Full Text] [Related]
19. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
20. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
